BCRX – BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc.BCRX
$7.59Name : BioCryst Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $1,951,614,976.00
EPSttm : -1.28
BioCryst Pharmaceuticals, Inc.
$7.59
0.73%$0.055
BCRX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
12.03
Margin Of Safety %
-19
Put/Call OI Ratio
0.15
EPS Next Q Diff
0.02
EPS Last/This Y
-0.51
EPS This/Next Y
0.07
Price
7.53
Target Price
20.45
Analyst Recom
1.36
Performance Q
-28.9
Upside
-760.0%
Beta
0.52
Ticker: BCRX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | BCRX | 8.35 | 0.13 | 0.48 | 53315 |
| 2026-10-13 | BCRX | 8.06 | 0.13 | 0.15 | 53576 |
| 2026-10-14 | BCRX | 8.06 | 0.13 | 0.50 | 53582 |
| 2026-10-15 | BCRX | 8.02 | 0.12 | 0.49 | 53670 |
| 2026-10-16 | BCRX | 7.78 | 0.12 | 0.81 | 53657 |
| 2026-10-19 | BCRX | 8.07 | 0.14 | 0.05 | 45740 |
| 2026-10-20 | BCRX | 7.93 | 0.14 | 0.17 | 46966 |
| 2026-10-21 | BCRX | 7.73 | 0.14 | 0.11 | 46933 |
| 2026-10-22 | BCRX | 7.78 | 0.14 | 3.42 | 47137 |
| 2026-10-23 | BCRX | 7.65 | 0.14 | 0.60 | 47059 |
| 2026-10-26 | BCRX | 7.89 | 0.14 | 0.32 | 47774 |
| 2026-10-27 | BCRX | 8.09 | 0.14 | 0.70 | 48007 |
| 2026-10-28 | BCRX | 8.38 | 0.14 | 0.00 | 47842 |
| 2026-10-29 | BCRX | 8.53 | 0.13 | 0.99 | 49219 |
| 2026-10-30 | BCRX | 8.47 | 0.13 | 0.43 | 49049 |
| 2026-11-02 | BCRX | 8.24 | 0.13 | 4.30 | 49106 |
| 2026-11-03 | BCRX | 8.61 | 0.14 | 0.09 | 49240 |
| 2026-11-04 | BCRX | 8.27 | 0.14 | 0.38 | 49234 |
| 2026-11-05 | BCRX | 7.31 | 0.15 | 0.86 | 50203 |
| 2026-11-06 | BCRX | 7.68 | 0.15 | 0.76 | 50674 |
| 2026-11-09 | BCRX | 7.64 | 0.15 | 0.71 | 50827 |
| 2026-11-10 | BCRX | 7.57 | 0.15 | 4.28 | 51131 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | BCRX | 8.35 | -28.1 | - | 0.74 |
| 2026-10-13 | BCRX | 8.09 | -28.1 | - | 0.74 |
| 2026-10-14 | BCRX | 8.06 | -28.1 | - | 0.74 |
| 2026-10-15 | BCRX | 8.01 | -28.1 | - | 0.74 |
| 2026-10-16 | BCRX | 7.78 | -28.1 | - | 0.74 |
| 2026-10-19 | BCRX | 8.06 | -28.1 | - | 0.74 |
| 2026-10-20 | BCRX | 8.06 | -28.1 | - | 0.74 |
| 2026-10-21 | BCRX | 7.93 | -28.1 | - | 0.74 |
| 2026-10-22 | BCRX | 7.78 | -28.1 | - | 0.74 |
| 2026-10-23 | BCRX | 7.65 | -28.1 | - | 0.74 |
| 2026-10-26 | BCRX | 7.89 | -28.1 | - | 0.75 |
| 2026-10-27 | BCRX | 8.10 | -28.1 | - | 0.75 |
| 2026-10-28 | BCRX | 8.38 | -28.1 | - | 0.75 |
| 2026-10-29 | BCRX | 8.53 | -28.1 | - | 0.75 |
| 2026-10-30 | BCRX | 8.47 | -28.1 | - | 0.75 |
| 2026-11-02 | BCRX | 8.24 | -28.1 | - | 0.75 |
| 2026-11-03 | BCRX | 8.61 | -28.1 | - | 0.75 |
| 2026-11-04 | BCRX | 8.27 | -28.1 | - | 0.75 |
| 2026-11-05 | BCRX | 7.59 | -28.1 | - | 0.75 |
| 2026-11-06 | BCRX | 7.68 | -37.6 | - | 0.75 |
| 2026-11-09 | BCRX | 7.64 | -37.6 | - | 0.75 |
| 2026-11-10 | BCRX | 7.53 | -37.6 | - | 0.75 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | BCRX | -0.20 | 5.12 | 12.52 |
| 2026-10-13 | BCRX | -0.20 | 5.12 | 12.52 |
| 2026-10-14 | BCRX | -0.20 | 5.12 | 12.52 |
| 2026-10-15 | BCRX | -0.20 | 5.12 | 12.52 |
| 2026-10-16 | BCRX | -0.20 | 5.12 | 12.52 |
| 2026-10-19 | BCRX | -0.20 | 5.32 | 12.52 |
| 2026-10-20 | BCRX | -0.20 | 5.32 | 12.52 |
| 2026-10-21 | BCRX | -0.20 | 5.32 | 12.52 |
| 2026-10-22 | BCRX | -0.20 | 5.32 | 12.52 |
| 2026-10-23 | BCRX | -0.20 | 5.32 | 12.52 |
| 2026-10-26 | BCRX | -0.20 | 5.26 | 12.52 |
| 2026-10-27 | BCRX | -0.20 | 5.26 | 12.11 |
| 2026-10-28 | BCRX | -0.20 | 5.26 | 12.11 |
| 2026-10-29 | BCRX | -0.20 | 5.26 | 12.11 |
| 2026-10-30 | BCRX | -0.20 | 5.26 | 12.11 |
| 2026-11-02 | BCRX | -0.20 | 5.33 | 12.11 |
| 2026-11-03 | BCRX | -0.20 | 5.33 | 12.11 |
| 2026-11-05 | BCRX | -0.20 | 5.33 | 12.11 |
| 2026-11-06 | BCRX | -0.20 | 5.33 | 12.11 |
| 2026-11-09 | BCRX | -0.20 | 3.88 | 12.03 |
| 2026-11-10 | BCRX | -0.20 | 3.88 | 12.03 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.14
Avg. EPS Est. Current Quarter
0.13
Avg. EPS Est. Next Quarter
0.16
Insider Transactions
-0.2
Institutional Transactions
3.88
Beta
0.52
Average Sales Estimate Current Quarter
169
Average Sales Estimate Next Quarter
167
Fair Value
6.13
Quality Score
72
Growth Score
53
Sentiment Score
8
Actual DrawDown %
62.4
Max Drawdown 5-Year %
-79.1
Target Price
20.45
P/E
Forward P/E
13.38
PEG
P/S
2.02
P/B
P/Free Cash Flow
5.55
EPS
-1.42
Average EPS Est. Cur. Y
0.75
EPS Next Y. (Est.)
0.82
Target Price Estimates Raised
Target Price Estimates Lowered
1
Profit Margin
-37.41
Relative Volume
0.58
Return on Equity vs Sector %
64.2
Return on Equity vs Industry %
83.8
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
◆
BCRX
Healthcare
$7.53
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
38.5
Range 1M
11.2%
Sup Dist
0.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-289.2%
EPS NY
124.6%
52W%
26.4%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+169.3% upside
Upside
+169.3%
Quality
72
MoS
-19%
BCRX — P/E HistoricalBiotechnology
BioCryst Pharmaceuticals, Inc.Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 435
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
BCRX
Latest News
—
Caricamento notizie per BCRX…
stock quote shares BCRX – BioCryst Pharmaceuticals, Inc. Stock Price stock today
news today BCRX – BioCryst Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch BCRX – BioCryst Pharmaceuticals, Inc. yahoo finance google finance
stock history BCRX – BioCryst Pharmaceuticals, Inc. invest stock market
stock prices BCRX premarket after hours
ticker BCRX fair value insiders trading